
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is poised for success, with the recent FDA's RMAT designation for their allogeneic BCMA-targeted CAR-T asset, CB-011, further mitigating regulatory risk and showcasing superior efficacy results compared to competitors. With upcoming catalysts, such as longer follow-up data from the ANTLER trial and initial dose expansion data for CB-011, there is strong potential for further positive developments and a successful path to market. As such, it is recommended to maintain a Buy rating and a 12-month price target of $9 per share.
Bears say
Caribou Biosciences is facing several challenges that contribute to a negative outlook, including the uncertainty and risk associated with developing and commercializing new therapies in the biopharmaceutical industry, potential competition from other companies in the CRISPR gene-editing space, and the company's historical lack of profitability. Additionally, the company's reliance on a single segment of business and its heavy dependence on the US market could limit its growth potential and make it vulnerable to fluctuations in the domestic market. Overall, these factors could significantly impact Caribou Biosciences' future financial performance and the success of its product candidates.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares